Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Boditech Med Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Recent updates

Does Boditech Med (KOSDAQ:206640) Have A Healthy Balance Sheet?

Sep 13

Investor Optimism Abounds Boditech Med Inc. (KOSDAQ:206640) But Growth Is Lacking

Jul 12

Boditech Med Inc. (KOSDAQ:206640) Shares Fly 49% But Investors Aren't Buying For Growth

Apr 16

Here's Why I Think Boditech Med (KOSDAQ:206640) Might Deserve Your Attention Today

Apr 13

Could The Market Be Wrong About Boditech Med Inc. (KOSDAQ:206640) Given Its Attractive Financial Prospects?

Mar 01

Boditech Med (KOSDAQ:206640) Seems To Use Debt Rather Sparingly

Jan 18

Here's Why I Think Boditech Med (KOSDAQ:206640) Is An Interesting Stock

Dec 28

Did Business Growth Power Boditech Med's (KOSDAQ:206640) Share Price Gain of 193%?

Dec 08

Boditech Med Inc. (KOSDAQ:206640) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Nov 18

CEO

Boditech Med CEO'su yok ya da onlar hakkında elimizde veri yok.

Boditech Med Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Boditech Med Inc., Annual General Meeting, Mar 29, 2021

Recent updates

Does Boditech Med (KOSDAQ:206640) Have A Healthy Balance Sheet?

Investor sentiment deteriorates as stock falls 16%

Investor Optimism Abounds Boditech Med Inc. (KOSDAQ:206640) But Growth Is Lacking

SphingoTec GmbH Introduces Kidney Function Biomarker penKid Together with Boditech Med Inc. At the 42nd AKI & CRRT Course in Vicenza

Upcoming dividend of ₩150 per share at 0.7% yield

Third quarter 2023 earnings released: EPS: ₩420 (vs ₩266 in 3Q 2022)

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 25%

Investor sentiment improves as stock rises 19%

Full year 2022 earnings released: EPS: ₩1,080 (vs ₩1,937 in FY 2021)

Investor sentiment improved over the past week

Upcoming dividend of ₩200 per share

Boditech Med Inc. (KOSDAQ:A206640) announces an Equity Buyback for KRW 5,000 million worth of its shares.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of ₩200 per share

Third quarter 2021 earnings released: EPS ₩624 (vs ₩619 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Boditech Med Inc. (KOSDAQ:206640) Shares Fly 49% But Investors Aren't Buying For Growth

Boditech Med Inc. (KOSDAQ:A206640) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Here's Why I Think Boditech Med (KOSDAQ:206640) Might Deserve Your Attention Today

Investor sentiment improved over the past week

Could The Market Be Wrong About Boditech Med Inc. (KOSDAQ:206640) Given Its Attractive Financial Prospects?

Investor sentiment deteriorated over the past week

New 90-day low: ₩18,200

Boditech Med Inc., Annual General Meeting, Mar 29, 2021

Boditech Med (KOSDAQ:206640) Seems To Use Debt Rather Sparingly

New 90-day low: ₩21,000

Here's Why I Think Boditech Med (KOSDAQ:206640) Is An Interesting Stock

Investor sentiment deteriorated over the past week

New 90-day low: ₩23,650

Did Business Growth Power Boditech Med's (KOSDAQ:206640) Share Price Gain of 193%?

New 90-day low: ₩23,950

Boditech Med Inc. (KOSDAQ:206640) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Market pulls back on stock over the past week

Market bids up stock over the past week

Choi Eui Yul and three related parties acquired 27% stake in Boditech Med Inc. (KOSDAQ:A206640).

Kim Jae Hak and 11 related parties acquired 11.66% stake in Boditech Med Inc. (KOSDAQ:A206640).

New 90-day high - ₩29,150

CEO